Scottsdale, Arizona (PRWEB) October 06, 2012
QualityStocks would like to highlight BIO-key International, Inc., a publicly traded company engaged in the development and marketing of fingerprint identification biometric technology and software solutions. Its products include Vector Segment Technology SDK, a biometric software development kit; True User Identification, a biometric identification solution that offers large-scale one-to-many user lookup with a single fingerprint; and WEB-key, a Web-based biometric security platform for managing fingerprint authentication across unprotected networks, including the Internet.
In the company’s news Friday,
BIO-key International told investors that it will be a presenting company at the American Association of Blood Banks – Annual Meeting and CTTXPO, at the Boston Convention Center, October 6th – 9th, 2012 (Booth # 1221). The event brings together blood donor industry members to learn about the latest advances in blood banking, transfusion medicine, and cellular therapies, as well as to explore state-of-the-art products and services.
Eric Schulties, CIO at the Institute for Transfusion Medicine and winner of the CIO of the Year 2012 award in Pittsburgh, Pennsylvania, will be directing and Michele Tysarczyk, RN, BA, Executive Director, Blood Operations at Central Blood Bank, has been given the responsibility of moderating a discussion for Nurses, Managers/Supervisors, and CEOs/CFOs. The panel of speakers will include Anne Lassinger, BS, MT (ASCP); Mary Plut, MT (ASCP), CQE (ASQ); Eric Schulties, MBA, MHA; Roxanne Tata, MT(ASCP)SBB, CQA (ASQ).
This forum will begin with brief presentation of how one organization moved from a first-stage electronic donor record to a more advanced system that includes biometrics for donor and staff identification. Panelists will discuss the integration of third-party medical devices, in addition to the overall impact these projects had on key performance indicators, such as duplicate donors and documentation errors. Topics to be covered include: why biometrics and integration with medical devices were selected as strategic projects, how these projects were set up and positioned for success, and finally the group will share the key technology, process and organization decisions that were made.
Headquartered in Wall, New Jersey, BIO-key International develops and delivers advanced identification solutions to commercial and government enterprises, integrators, and custom application developers. The company’s award winning, high performance, scalable, cost-effective, and easy-to-deploy biometric finger identification technology accurately identifies and authenticates users of wireless and enterprise applications.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.